Eikon Therapeutics Inc has 8 Schedule 13D or 13G filings on record since 2026-02-11. 7 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Column Group IV GP, LP | 11.6% | 4,460,979 | SCHEDULE 13D, 2026-02-12 | 2026-02-06 |
| Fmr LLC | 9.2% | 4,993,906 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| James B. Tananbaum | 7.7% | 4,148,519 | SCHEDULE 13G, 2026-02-11 | 2026-02-04 |
| BlackRock Portfolio Management LLC | 5.5% | 3,002,737 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Abu Dhabi Investment Authority | 5.2% | 2,816,714 | SCHEDULE 13G, 2026-02-18 | 2026-02-04 |
| Perlmutter Roger M | 5.2% | 2,893,171 | SCHEDULE 13G, 2026-05-13 | 2026-02-04 |
| Innovation Endeavors III LP | 5% | 2,723,226 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
Purpose of Transaction (Item 4)
The Column Group IV GP, LP
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-02-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-11 | James B. Tananbaum | 7.7% | SCHEDULE 13G |
| 2026-02-12 | The Column Group IV GP, LP | 11.6% | SCHEDULE 13D |
| 2026-02-18 | Abu Dhabi Investment Authority | 5.2% | SCHEDULE 13G |
| 2026-04-29 | BlackRock Portfolio Management LLC | 5.5% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 7.1% | SCHEDULE 13G |
| 2026-05-13 | Perlmutter Roger M | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Innovation Endeavors III LP | 5% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 9.2% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Eikon Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.